P1.05-016 Circulating BARD1 Antibodies for Early Detection of Lung Cancer
نویسندگان
چکیده
منابع مشابه
BARD1 serum autoantibodies for the detection of lung cancer
PURPOSE Currently the screening for lung cancer for risk groups is based on Computed Tomography (CT) or low dose CT (LDCT); however, the lung cancer death rate has not decreased significantly with people undergoing LDCT. We aimed to develop a simple reliable blood test for early detection of all types of lung cancer based on the immunogenicity of aberrant forms of BARD1 that are specifically up...
متن کاملCirculating microRNAs: next-generation biomarkers for early lung cancer detection
Early diagnosis of lung cancer by low-dose computed tomography is an effective strategy to reduce cancer mortality in high-risk individuals. However, recruitment of at-risk individuals with asymptomatic lung cancer still remains challenging. We developed a minimal invasive serum test, based on the detection of circulating microRNAs, which can identify at-risk individuals with asymptomatic early...
متن کاملLung Cancer Early Detection: The Role of Circulating MicroRNAs
Lung cancer screening with low-dose Computed Tomography signature. The cohorts were recruited from different health centers (LDCT) was recently shown to be effective in reducing lung cancer mortality (Aberle et al., 2011). An ~20% of reduction of mortality was observed at 3 years in the LDCT arm of a randomized multicenter study, the National Lung Cancer Screening Trial (NLST), which enrolled ~...
متن کاملDetection of early lung cancer.
Background. The Early Lung Cancer Action Project (ELCAP) is designed to evaluate baseline and annual repeat screening by low-radiation-dose computed tomography (low-dose CT) in people at high risk of lung cancer. We report the baseline experience. Methods. ELCAP has enrolled 1000 symptom-free volunteers, aged 60 years or older, with at least 10 pack-years of cigarette smoking and no previous ca...
متن کاملCirculating miRNA signature for early diagnosis of lung cancer
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. Despite the numerous recent studies on NSCLC genomics, molecular mechanisms of disease and the development of targeted therapies, which improve treatment responses to a certain extent, the overall 5-year survival rate is only around 10–15%. The main reason for such a low 5-year survival rate has long been att...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.800